Contact this trialFirst, we need to learn more about you.
Amlitelimab for Asthma
Recruiting0 awardsPhase 2
Toronto, Ontario
This trial is a Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study assessing the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. The study duration is up to approximately 76 weeks for participants not going into the long-term safety (LTS) study and up to approximately 64 weeks for participants going into the LTS study. The scheduled number of visits is 13.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.